Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 234,930,495 papers from all fields of science
Search
Sign In
Create Free Account
ABT-869
Known as:
ABT 869
, ABT869
, multitargeted receptor tyrosine kinase inhibitor ABT-869
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
linifanib
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Phase II trial of linifanib in patients with advanced renal cell cancer (RCC) after sunitinib failure.
N. Tannir
,
Y. Wong
,
+7 authors
D. Michaelson
2010
Corpus ID: 73859419
4527 Background: Linifanib (ABT-869) is a potent inhibitor of VEGF and PDGF receptor tyrosine kinases. Phase I study results…
Expand
2010
2010
Total lesion glycolysis and FDG SUV as early readouts of tumor response to Linifanib (ABT-869) in SCID mice with HT1080 xenografts
Yumin Zhang
,
Todd B. Cole
,
+6 authors
G. Fox
2010
Corpus ID: 73897334
2009
2009
PTEN underexpression was associated with more aggressive tumor behaviour in hepatocellular carcinoma and PTEN suppressed cell invasion by downregulating NF- κ B signaling pathway
Antoinette L. Bolin
,
T. Gail
,
+5 authors
C. Donawho
2009
Corpus ID: 145043981
Results: Mitogen-activated protein kinase 13 (MAPK13) overexpression was observed in all our tumour specimens. Subgroup analysis…
Expand
2009
2009
Abstract #1789: Cellular activity of ABT-869 against colony-stimulating-factor-1 receptor (CSF-1R) in macrophage-like cell lines
Jun Guo
,
Yujia Dai
,
+11 authors
K. Glaser
2009
Corpus ID: 80685263
ABT-869 is a potent inhibitor of the VEGFR and PDGFR families of receptor tyrosine kinases, including c-fms (CSF-1R). Colony…
Expand
2008
2008
The effect of varying doses of ABT-869 on biomarkers of angiogenesis and their correlation with pharmacodynamic outcome
R. Soo
,
E. Mckeegan
,
+7 authors
B. Goh
2008
Corpus ID: 79096149
14535 Background: ABT-869, an orally administered, potent small molecule inhibitor of VEGF receptors 1–3 and platelet derived…
Expand
2007
2007
The RTK inhibitor ABT-869, alone and in combination with paclitaxel and/or zoledronic acid, demonstrates significant reduction in the development of both osteoblastic (LuCap 23.1) and osteolytic (PC3…
C. Donawho
,
J. Hickson
,
+6 authors
D. Frost
2007
Corpus ID: 86297994
C204 ABT-869 (ABT), a receptor tyrosine kinase inhibitor (RTKI) currently in Phase 1 clinical trials, is a potent inhibitor of…
Expand
2007
2007
The RTK inhibitor, ABT-869 alone or in combination with various cytotoxic therapies demonstrate significant tumor growth inhibition in orthotopic hepatocellular carcinoma, renal cell carcinoma and…
C. Donawho
,
Yi-Chun Wang
,
+8 authors
D. Frost
2007
Corpus ID: 87001313
C201 The RTKI, ABT-869, is a potent inhibitor of vascular endothelial growth factor (VEGF) and platelet-derived growth factor…
Expand
2006
2006
ABT-869, a novel multi-target receptor tyrosine kinase inhibitor (RTKI), combined with chemotherapy is synergistic in the therapy of acute myeloid leukemia cells with FLT3-ITD mutation (FLT3-AML).
Jianbiao Zhou
,
M. Pan
,
+7 authors
Chien-Shing Chen
Journal of Clinical Oncology
2006
Corpus ID: 30482511
13064 Background: Internal tandem duplications (ITDs) of fms-like tyrosine kinase 3 (FLT3) receptor are identified in 20-25% of…
Expand
2005
2005
Preclinical activity of ABT-869, a novel receptor tyrosine kinase inhibitor, alone or in combination with paclitaxel
Jason A. Stavropoulos
,
J. Meulbroek
,
+7 authors
C. Donawho
2005
Corpus ID: 74161267
3175 Background: ABT-869, a multi-targeted receptor tyrosine kinase inhibitor, has been shown to inhibit of all members of the…
Expand
2005
2005
ABT-869 a novel multi-targeted receptor tyrosine kinase inhibitor: characterization of FLT3 phosphorylation in a model of acute myelogenous leukemia
Junling Li
,
L. Pease
,
+8 authors
K. Glaser
2005
Corpus ID: 83263956
Proc Amer Assoc Cancer Res, Volume 46, 2005 5981 Acute myeloid leukemia (AML) is associated with dysregulated hematopoietic…
Expand